We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
NVOS | Novo Integrated Sciences Inc | 1.05 | 0.599 | 132.82% | 310,284,633 |
BNAI | Brand Engagement Network Inc | 5.4799 | 2.90 | 112.40% | 67,994,392 |
PRTG | Portage Biotech Inc | 0.51 | 0.253 | 98.44% | 4,260,166 |
PLTNU | Plutoniam Acquisition Corporation | 12.06 | 5.42 | 81.63% | 1,810 |
PEGRU | Project Energy Reimagined Acquisition Corporation | 11.43 | 3.08 | 36.89% | 1,191 |
SLNA | Selina Hospitality PLC | 0.0945 | 0.0226 | 31.43% | 113,414,895 |
CYCC | Cyclacel Pharmaceuticals Inc | 2.6399 | 0.6199 | 30.69% | 2,367,157 |
VCNX | Vaccinex Inc | 6.78 | 1.58 | 30.38% | 454,991 |
GNPX | Genprex Inc | 3.14 | 0.72 | 29.75% | 3,384,633 |
XCUR | Exicure Inc | 0.4501 | 0.0991 | 28.23% | 341,223 |
DRRX | Durect Corp | 1.73 | 0.38 | 28.15% | 565,903 |
As previously reported, the Board of Directors (the “Board”) of Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) approved the repurchase of up to $5 million of the Company’s outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions (the “Stock Repurchase Program”). The Company today announced that the Board is conducting a strategic review to determine whether it is appropriate to increase the maximum amount that can be repurchased pursuant to the Stock Repurchase Program based on the amount, if any, of excess funds that may be ...
Brand Engagement Network Inc. (“BEN”) (Nasdaq: BNAI), an emerging provider of personalized customer engagement AI, today announced it has closed a private placement with existing investors of its common stock and warrants to purchase common stock in the aggregate amount of $4.95 million, providing the Company with increased financial flexibility to continue the development of its human-like, business-safe conversational AI assistants. Concurrently, BEN announced that Paul Chang has been promoted to Co-CEO, bringing his unique perspective to the leadership team alongside Co-CEO Michael Zacharski.
Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas, May 30, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming 2024 BIO International Convention.
First Quarter Fiscal 2025 Total Revenue of $450.6 million, up 22% Year-over-Year Continued Strong Customer Growth with Over 49,200 Customers as of April 30, 2024 MongoDB Atlas Revenue up 32% Year-over-Year; 70% of Total Q1 Revenue NEW YORK, May 30, 2024 /PRNewswire/ -- MongoDB, Inc. (NASDAQ: MDB) today announced its financial results for the first quarter ended April 30, 2024.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 67,705.32 | 223.66 | 0.33% | 1.33T | 3,735,877,754 |
ETH | Ethereum | 3,778.99 | 19.56 | 0.52% | 453.3B | 2,219,887,084 |
USDT | Tether USD | 0.99923 | 0.00025 | 0.03% | 97.76B | 270,951,535 |
BNB | Binance Coin | 594.79 | 1.36 | 0.23% | 93.83B | 138,379,348 |
SOL | Solana | 167.35 | 1.85 | 1.12% | 73.62B | 788,437,551 |
STETH | stETH | 3,775.68 | 17.75 | 0.47% | 37B | 9,102,814 |
XRP | Ripple | 0.5194 | 0.0022 | 0.43% | 28.31B | 262,792,177 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 833,819,785 |
DOGE | Dogecoin | 0.15931 | 0.00031 | 0.19% | 22.78B | 265,367,453 |
TONCOIN | Wrapped TON Coin | 6.32 | -0.059418 | -0.93% | 21.82B | 44,533,531 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions